Oplunofusp - Ansun Biopharma
Alternative Names: DAS 181-F02; DAS-181; DAS181-F04; Fludase; NEX DAS181; ParaDaseLatest Information Update: 28 Mar 2024
Price :
$50 *
At a glance
- Originator NexBio
- Developer Ansun Biopharma; NexBio
- Class Antivirals; Recombinant fusion proteins
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID 2019 infections; Parainfluenza virus infections
- Phase II Influenza virus infections
- No development reported Enterovirus infections; Metapneumovirus infections
- Discontinued Polyomavirus infections; Respiratory syncytial virus infections
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Enterovirus infections in USA
- 28 Mar 2024 No recent reports of development identified for phase-I development in Metapneumovirus-infections in USA
- 28 May 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections in USA (Inhalation)